Methylphenidate in Childhood Apraxia of Speech
Key facts
- Who runs it
- Murdoch Childrens Research Institute
- Where
- Australia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 18 people enrolled
- Started
- 14 Mar 2022
- Ended
- 27 Oct 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- Methylphenidate Hydrochloride
- Placebo
- Record updated
- 13 October 2026
Who can take part
- Age
- 6 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Has childhood apraxia of speech
- Aged 6-12 years
- Can perform the speech tasks for the trial (able to speak single words and short sentences)
- English as a first language
- Has adequate hearing
- Has a legally acceptable representative capable of understanding the informed consent document and providing consent on their behalf
- Passes the health and medical examination including examination of heart rate and blood pressure for age and weight norms
- Can commit to the time requirements of the trial
- Lives within 250 kilometres of the study site (MCRI)
- Able to swallow a capsule
- Scores 13 or more out of 27 on either the inattention and/or hyperactivity subscales of the SNAP-IV Parent 18-Item Rating Scale, suggesting clinically significant symptoms of inattention and/or hyperactivity
Who cannot take part
- Has a diagnosis of severe intellectual disability, or other significant neurodevelopmental conditions (e.g., Fragile X, Down Syndrome, etc.)
- Has epilepsy or other seizure disorders
- Is taking medication(s) for another health condition(s) that is known to interfere with MPH
- Has any contraindication to the stimulant (methylphenidate) medication, including severe anxiety, depression, severe Tourette syndrome, glaucoma, psychotic symptoms, hypertension, congenital heart disease, known past or present diagnosed substance abuse or dependence
- Is unable to commit to the time requirements of the trial (8 weeks + 2 days)
- Has a score of moderate or high risk of suicidality, assessed with the Columbia Suicidality Severity Rating Scale (C-SSRS)
- Has used psychostimulants within the past 3 months (e.g., Ritalin, Concerta, Focalin)
- Lives more than 250 kilometres from the study site
- Unable to swallow a capsule
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to describe the possible effects of methylphenidate (MPH) on speech intelligibility in children with childhood apraxia of speech (CAS) aged 6-12 years. This outcome will be compared between MPH intake and placebo intake.
The 2 groups in the trial
- Sequence A: Methylphenidate, PlaceboTreatment being tested
Participants will first receive methylphenidate capsules twice daily for four weeks. Doses will be administered four hours apart. The maximum dose is determined based on the participant's weight. After a 2-day washout, participants then receive Placebo (matching methylphenidate capsules) twice daily for four weeks.
Treatment: Methylphenidate Hydrochloride and Placebo
- Sequence B: Placebo, MethylphenidateTreatment being tested
Participants will first receive Placebo capsules twice daily for four weeks. Doses will be administered four hours apart. After a 2-day washout, participants then receive methylphenidate capsules (matching Placebo capsules) twice daily for four weeks. The maximum dose is determined based on the participant's weight.
Treatment: Methylphenidate Hydrochloride and Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II Proof-of-concept Trial of Methylphenidate in Children With Apraxia of Speech: a Double-blind, Randomised, Placebo-controlled, Cross-over Trial
- Record updated
- 13 October 2026